162 related articles for article (PubMed ID: 20453626)
1. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.
Tungsiripat M; Bejjani DE; Rizk N; O'riordan MA; Ross AC; Hileman C; Storer N; Harrill D; McComsey GA
AIDS; 2010 Jun; 24(9):1291-8. PubMed ID: 20453626
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
McComsey GA; O'Riordan M; Choi J; Libutti D; Rowe D; Storer N; Harrill D; Gerschenson M
Antivir Ther; 2012; 17(2):347-53. PubMed ID: 22293126
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
Mallon PW; Sedwell R; Rogers G; Nolan D; Unemori P; Hoy J; Samaras K; Kelleher A; Emery S; Cooper DA; Carr A;
J Infect Dis; 2008 Dec; 198(12):1794-803. PubMed ID: 18954260
[TBL] [Abstract][Full Text] [Related]
6. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA; Walker UA; Budhathoki CB; Su Z; Currier JS; Kosmiski L; Naini LG; Charles S; Medvik K; Aberg JA;
AIDS; 2010 Oct; 24(16):2507-15. PubMed ID: 20827170
[TBL] [Abstract][Full Text] [Related]
7. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Carr A; Workman C; Carey D; Rogers G; Martin A; Baker D; Wand H; Law M; Samaras K; Emery S; Cooper DA;
Lancet; 2004 Feb; 363(9407):429-38. PubMed ID: 14962523
[TBL] [Abstract][Full Text] [Related]
8. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.
Tungsiripat M; El-Bejjani D; Rizk N; Dogra V; O'Riordan MA; Ross AC; Hileman C; Storer N; Harrill D; McComsey GA
AIDS Res Hum Retroviruses; 2011 Mar; 27(3):295-302. PubMed ID: 20969457
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
[TBL] [Abstract][Full Text] [Related]
10. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
11. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
[TBL] [Abstract][Full Text] [Related]
12. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Haubrich RH; Riddler SA; DiRienzo AG; Komarow L; Powderly WG; Klingman K; Garren KW; Butcher DL; Rooney JF; Haas DW; Mellors JW; Havlir DV;
AIDS; 2009 Jun; 23(9):1109-18. PubMed ID: 19417580
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
14. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.
Yang Y; Yap M; Oo Tha N; Paton NI
HIV Clin Trials; 2008; 9(6):399-406. PubMed ID: 19203905
[TBL] [Abstract][Full Text] [Related]
15. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
Blümer RM; van der Valk M; Ackermans M; Endert E; Serlie MJ; Reiss P; Sauerwein HP
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1097-104. PubMed ID: 19690066
[TBL] [Abstract][Full Text] [Related]
16. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
Hulgan T; Haubrich R; Riddler SA; Tebas P; Ritchie MD; McComsey GA; Haas DW; Canter JA
AIDS; 2011 Jan; 25(1):37-47. PubMed ID: 20871389
[TBL] [Abstract][Full Text] [Related]
17. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
[TBL] [Abstract][Full Text] [Related]
18. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
19. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
